Remote rehabilitation for people receiving CAR-T cell therapy
Official title: Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy
Run by University of Utah · NCT07390071 · Data updated 2026-11-12
This project will test a home-based telerehabilitation program using interactive exercise, nutrition, behavioral support, and remote monitoring for people with lymphoma or myeloma who are getting CAR-T therapy.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 21 Years and up |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | University of Utah Academic / other |
| Drugs / interventions | CAR-T, CAR T, CART, chemotherapy |
| Locations | 1 site (Salt Lake City, Utah) |
| Status | Recruiting |
| Started | September 1, 2025 |
| Main results expected | January 2029 |
| Study ends | January 2029 |
| Registry record updated | February 5, 2026 |
| Trial ID | NCT07390071 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults over 21 with confirmed lymphoma or multiple myeloma who plan to receive a commercial FDA-approved CAR-T therapy at least four weeks after enrollment, have ECOG performance status 0–2, and have access to a working telephone or cell phone are ideal candidates.
✕Probably not a fit
Patients with unstable angina or recent myocardial infarction, uncontrolled hypertension, pacemakers, painful or unstable bony metastases or recent fractures, those already in a regular exercise rehabilitation program, planning to relocate within six months, or enrolled in another clinical trial are excluded and may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The program uses a web-based care portal and a Home Automated Telemanagement (HAT) patient unit to deliver individualized exercise and nutrition plans alongside behavioral counseling and education. Patients complete guided touch-screen sessions at home while the cloud-based Internet-of-Things system collects cardiovascular and performance data in real time. A validated AI-driven algorithm estimates exertion level to support exercise safety and tailor intensity, and clinicians monitor progress remotely through the portal. This pilot feasibility project will measure effects on disease-specific quality of life, functional ability, and symptom burden in patients around the time of CAR-T therapy.
Why it matters
Potential benefit: If successful, the program could help patients maintain or improve physical function, reduce symptoms and fatigue, and preserve quality of life during and after CAR-T therapy while reducing the need for frequent clinic visits.
How similar studies have gone: Exercise and telehealth interventions have improved quality of life and reduced fatigue in other cancer populations, but delivering multimodal telerehabilitation specifically for patients undergoing CAR-T therapy is a novel, early-stage approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * age \>21 * confirmed diagnosis of lymphoma or myeloma * commercial FDA-approved CAR-T delivery planned for ≥4 weeks following enrollment * Eastern Cooperative Oncology Group (ECOG) performance status 0-2. * Access to a working telephone line in their home or a cell phone. Exclusion Criteria: * have unstable angina, uncontrolled hypertension, recent myocardial infarction, pacemakers, painful or unstable bony metastases, or recent skeletal fractures; * are engaged in a regular exercise rehabilitation program; * have relocation plans within next 6 months; * participate in another clinical trial.
Where it's running
-
Huntsman Cancer Institute at University of Utah
Salt Lake City, Utah, United States Recruiting
Study contacts
- Principal investigator: Douglas Sborov, MD, MS — Huntsman Cancer Institute
- Study coordinator: Aileen Gabriel
- Email: aileen.gabriel@utah.edu
- Phone: 801-585-3229
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Prophylactic use of Tocilizumab to prevent complications after CAR-T therapy
This study is testing if giving Tocilizumab before or during CAR-T therapy can help prevent serious side effects like cytokine release syndrome and neurotoxicity in patients with B-cell cancers.
-
CAR-T therapy outcomes and quality of life in older adults with B‑cell lymphoma
This project will see how CAR‑T therapy affects older adults (age 60+) with relapsed or refractory B‑cell lymphomas, focusing on daily function and quality of life while they receive standard care.
-
CD19/CD22 CAR-T consolidation after second-line therapy for high-risk aggressive B-cell lymphoma
This trial tests whether CD19/CD22 CAR-T cell therapy given after a second-line response can help people with high-risk aggressive B-cell lymphoma stay in remission.
-
In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma
This early-phase trial tests a one-time in vivo CAR T-cell therapy (SL1617) for people with relapsed or refractory B-cell lymphoma to see if it is safe and tolerable.
-
Genetics of Blood Cancers in the U.S. population
This study tests how genetic factors relate to blood cancers by collecting saliva DNA and online health surveys from at least 10,000 U.S. adults.
-
CD19/CD22 CAR-T as first-line consolidation for follicular lymphoma
This trial tests whether CAR-T cells targeting CD19 and CD22 can be used as a first-line consolidation therapy for people with follicular lymphoma to see if it improves outcomes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.